➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Harvard Business School
Colorcon
AstraZeneca
Moodys

Last Updated: January 15, 2021

DrugPatentWatch Database Preview

RAXIBACUMAB Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: RAXIBACUMAB
Patents:10
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for RAXIBACUMAB
Recent Clinical Trials for RAXIBACUMAB

Identify potential brand extensions & biosimilar entrants

SponsorPhase
GlaxoSmithKlinePhase 4
Human Genome Sciences Inc., a GSK CompanyPhase 3
GlaxoSmithKlinePhase 3

See all RAXIBACUMAB clinical trials

Pharmacology for RAXIBACUMAB
Mechanism of ActionAnthrax Protective Antigen-directed Antibody Interactions

Patent Text Search: US Patents for RAXIBACUMAB

These patents were identified by searching patent claims
Glossary
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Human Genome Sciences Inc. RAXIBACUMAB raxibacumab INJECTABLE; IV (INFUSION) 125349 001 2012-12-14   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX search
Human Genome Sciences Inc. RAXIBACUMAB raxibacumab INJECTABLE; IV (INFUSION) 125349 001 2012-12-14   Start Trial University of Kentucky Research Foundation (Lexington, KY) 2033-03-13 RX search
Human Genome Sciences Inc. RAXIBACUMAB raxibacumab INJECTABLE; IV (INFUSION) 125349 001 2012-12-14   Start Trial The Regents of the University of California (Oakland, CA) 2035-02-24 RX search
Human Genome Sciences Inc. RAXIBACUMAB raxibacumab INJECTABLE; IV (INFUSION) 125349 001 2012-12-14   Start Trial LA JOLLA BIOLOGICS, INC. (San Diego, CA) 2036-04-26 RX search
Human Genome Sciences Inc. RAXIBACUMAB raxibacumab INJECTABLE; IV (INFUSION) 125349 001 2012-12-14   Start Trial Aegis Therapeutics LLC (San Diego, CA) 2026-06-23 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Harvard Business School
Express Scripts
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2021 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
 NCE-1 Patent Challenge Dates 2021 - 2022
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group